Forecast
The analysts' average price target is €27.80 (+309.43%). The median is €27.80 (+309.43%).
| Buy |
Â
12 |
| Hold |
Â
5 |
| Sell |
Â
4 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Arcturus Therapeutics presents pipeline at Cantor conference; pivotal data expected soon
Arcturus Therapeutics presented three core programs at the Cantor Global Healthcare Conference: ARCT-810 for OTC deficiency, an inhaled mRNA program for cystic fibrosis (CF), and a self-amplifying mRNA platform with commercial vaccine success. Near-term catalysts include the Phase II readout for ARCT-810 expected later this month, FDA feedback, and a fourth-quarter decision on whether to continue the CF program — a move that could trigger funding from Thermo Fisher. Management highlights technological advantages (biodegradable LNPs, improved mRNA purification, a tailored nebulizer) but still sees risks around efficacy, safety and competition. » More on de.investing.com
Arcturus Therapeutics sees 2026 as a turning point with two near-term catalysts
At the Citigroup conference, Arcturus Therapeutics announced two near-term catalysts: Phase II data on OTC deficiency in September and a go/no-go decision on initiating Phase III for cystic fibrosis in the fourth quarter. The inhaled mRNA platform was presented as differentiated after safety and tolerability issues were addressed. Thermo Fisher has committed up to $40 million to non-dilutively support the Phase III cystic fibrosis development in exchange for exclusive manufacturing rights. The vaccine business provides non-dilutive revenue to fund the therapeutic pipeline; substantial CF data are expected in early 2025. » More on de.investing.com
Arcturus Therapeutics jumps after management signal and conference announcements
Arcturus Therapeutics’ stock rose intraday by about 10–13% after management announced participation in five major investor conferences in September, viewed as a vote of confidence in the pipeline. Key clinical milestones for ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency) are approaching. Analyst support, better-than-expected quarterly results, more than $191 million in cash and a strategic manufacturing agreement with Thermo Fisher bolster the funding outlook through 2028 and the credibility for a potential phase 3 study. The rally occurred despite a weaker broader market and appears to be company-specific. » More on de.investing.com
Arcturus highlights strong liquidity and upcoming clinical catalysts
Arcturus has more than $200 million in liquidity, giving it a funding runway into 2028 to support development of its programs. The company expects a Q4 2024 decision on advancing ARCT-032 (inhaled mRNA for cystic fibrosis) into phase III and anticipates data and regulatory guidance for ARCT-810 (OTC deficiency) before Sept. 30, 2024. The vaccine business, including KOSTAIVE (approved in 32 countries), has been returned to 100% strategic control and is intended to help fund the therapeutics pipeline. Arcturus is evaluating partnerships and has outlined a possible $40 million support from Thermo Fisher tied to a phase III decision. » More on de.investing.com
Arcturus Therapeutics reduces quarterly loss more than expected despite 89% revenue drop
Arcturus reported an adjusted loss of $0.84 per share in Q2 versus a consensus expectation of $1.05, beating estimates by 20%. Revenue fell to $2.96 million, a decline of 89.4% year‑on‑year after the end of the collaboration with CSL Seqirus. Cash and equivalents amounted to $191.5 million, securing a liquidity runway of more than 2.5 years. The company cut R&D spending, is advancing cystic fibrosis (ARCT‑032) and OTCD (ARCT‑810) programs, and expects Phase II/III decisions and data in the second half of 2026. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsIn 2012, Arcturus Therapeutics has already paid €2.66 in dividends. The last payout was in December 2012.
Financials
In the last quarter, Arcturus Therapeutics had revenue of €16.15M and net profit of -€6.55M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 16.15M | 10.53% |
| Gross profit | 16.15M | 37.28% |
| Net profit | -6.55M | 42.88% |
| EBITDA | -6.55M | 39.45% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €211.19M |
Number of shares | 28.82M |
52-week high/low | €16.37 - €5.01 |
| Dividends | No |
Beta | 2.61 |
P/E ratio | -2.59 |
PEG ratio | 0.10 |
P/B ratio | 1.36 |
P/S ratio | 9.29 |
Company profile
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
| Name | Arcturus Therapeutics |
| CEO | Joseph E. Payne |
| Headquarters | San Diego,
ca USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 05/22/2013 |
| Employees | 109 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ARCT |